herombopag olamine tablets
Sponsors
Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd., Hebei Medical University Fourth Hospital, Institute of Hematology & Blood Diseases Hospital, China, Fujian Cancer Hospital
Conditions
Adult Patients With Chronic Primary ITPAdult Patients With SAA Who do Not Respond Well to Immunosuppressive TherapyBreast CancerCTIT-Chemotherapy Induced ThrombocytopeniaCancer, Therapy-RelatedHerombopagNasopharyngeal Carcinoma (NPC)Non-small Cell Lung Cancer
Phase 1
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects
NCT06062680
Start: 2023-10-31End: 2023-11-15Target: 15Updated: 2023-10-02
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.
Not yet recruitingNCT06346925
Start: 2024-04-30End: 2024-07-31Target: 18Updated: 2024-04-04
Phase 2
An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC
NCT05252091
Start: 2022-02-20End: 2022-09-20Target: 30Updated: 2022-02-23
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
RecruitingNCT06838949
Start: 2025-03-03End: 2027-12-31Target: 80Updated: 2025-03-13
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
Not yet recruitingNCT07243418
Start: 2025-11-30End: 2028-05-30Target: 72Updated: 2025-11-21
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
Not yet recruitingNCT07252375
Start: 2025-11-30End: 2028-11-30Target: 35Updated: 2025-11-26
Herombopag Treated T-DM1 Induced Platelet Reduction
RecruitingNCT07257809
Start: 2025-10-13End: 2027-09-26Target: 56Updated: 2025-12-02